Matches in Nanopublications for { ?s ?p "DDI between Dihydroergotamine and Naratriptan - Naratriptan, a serotonin 5-HT1D receptor agonists, may increase the vasoconstricting effect of dihydroergotamine. Concomitant use of these two agents within 24 hours is contraindicated. [drugbank_resource:DB00320_DB00952]"@en ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- drugbank_resource:DB00320_DB00952 label "DDI between Dihydroergotamine and Naratriptan - Naratriptan, a serotonin 5-HT1D receptor agonists, may increase the vasoconstricting effect of dihydroergotamine. Concomitant use of these two agents within 24 hours is contraindicated. [drugbank_resource:DB00320_DB00952]" assertion.